Aquagenic Pruritus in Myeloproliferative Neoplasms

Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms Clinical Trial

— PANAM  

Official title:

Aquagenic Pruritus in Myeloproliferative Neoplasms

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04018209
• Other study ID #: PANAM (29BRC19.0001)
• Status: Recruiting
• Start date: July 9, 2019
• Est. completion date: January 9, 2020

Study information

• Verified date: July 2019
• Source: University Hospital, Brest
• Contact: Jean-Christophe IANOTTO
• Phone: +33298222523
• Email: jean-Christophe.ianotto[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Description of the characteristics of aquagenic pruritus expressed by patients suffering from myeloproliferative neoplasms.

Prospective work based on the distribution of a dedicated questionnaire.

Description:

Patients with myeloproliferative neoplasms identified and followed in French Hospitals. Patients could be followed for polycythemia vera or essential thrombocythemia or primary myelofibrosis.

Distribution of the questionnaire to each patient with myeloproliferative neoplasm (treated or not) suffering from aquagenic pruritus.

Analyse of each characteristic of the aquagenic pruritus by a statistician and publication at the end.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 125
• Est. completion date: January 9, 2020
• Est. primary completion date: January 9, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with one of three non-chromosomal Philadelphia-positive myeloproliferative neoplasms: polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).

• Suffering (or having suffered) from aquagenic pruritus.

• No age limit, but major

• Patient having formulated his non-opposition

Exclusion Criteria:

• Patients with MPN with non-aquagenic pruritus,

• Patients with another hematologic disease and aquagenic pruritus

• Patients unable to complete the questionnaire.

• Patients with physical or mental disabilities to formulate non-opposition

• Refusal of participation

Related Conditions & MeSH terms

• Deciphering Aquagenic Pruritus in Myeloproliferaitive Neoplasms
• Myeloproliferative Disorders
• Neoplasms
• Pruritus

Locations

Country	Name	City	State
France	06	Angers	Pays De La Loire
France	03	Annecy	Haute-Savoie
France	01	Brest
France	05	Lyon	Auvergne Rhônes-alpes
France	11	Morlaix	Bretagne
France	10	Quimper	Brestagne
France	08	Rochefort	Nouvelle Aquitaine
France	04	Roubaix	Hauts-de-France
France	09	Saint-Brieuc	Bretagne
France	07	Saint-Louis	Grand Est
France	02	Villejuif	Val-de-marne

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Brest

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Description of pruritus in patients with myeloproliferative neoplasms	Intensity of pruritus (visual analogic scale)	at the time of questionnaire completion (Day 0)
Secondary	Description of therapies used to treat pruritus	Name of drugs used	at the time of questionnaire completion (Day 0)